

**e PATIENT DEMOGRAPHICS**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_  
 Address: \_\_\_\_\_ City/ST/Zip: \_\_\_\_\_  
 Allergies: \_\_\_\_\_  NKDA Weight: \_\_\_\_\_  lbs  kg Height: \_\_\_\_\_  in  cm  
**Patient Status:**  New to Therapy  Dose or Frequency Change  Order Renewal

**INSURANCE INFORMATION: Please attach copy of insurance card (front and back).**

**DIAGNOSIS\***

**\*ICD 10 Code Required**  Plaque Psoriasis (L40.0-L40.4, L40.8-L40.9), ICD10 \_\_\_\_\_

**INFUSION ORDERS**

MEDICATION	DOSE	DIRECTIONS/DURATION
Ilumya® (tildrakizumab)	100mg	<input type="checkbox"/> <b>INITIAL:</b> Inject SUBQ at Weeks 0 and 4, then every 12 weeks thereafter x 1 year <input type="checkbox"/> <b>MAINTENANCE:</b> Inject SUBQ every 12 weeks x 1 year

**Is patient currently receiving therapy above from another facility?**  
 Yes  No  
 If yes, Facility Name: \_\_\_\_\_  
 Date of last treatment: \_\_\_\_\_ Date of next treatment: \_\_\_\_\_

**PRE-MEDICATION ORDERS**

No premeds ordered at this time  
 Acetaminophen 650mg PO  Diphenhydramine 25mg PO  
 Methylprednisolone 40mg IVP -OR-  Hydrocortisone 100mg IVP  
 Other: \_\_\_\_\_

**LAB ORDERS**

**Labs to be drawn by:**  Infusion Center  Referring Physician  
 No labs ordered at this time  
 CBC q \_\_\_\_\_  CMP q \_\_\_\_\_  CRP q \_\_\_\_\_  
 ESR q \_\_\_\_\_  LFTs q \_\_\_\_\_  Other: \_\_\_\_\_

**REFERRING PHYSICIAN INFORMATION**

Physician Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Physician Name: \_\_\_\_\_ NPI: \_\_\_\_\_ TIN: \_\_\_\_\_ Specialty: \_\_\_\_\_  
 Address: \_\_\_\_\_ City/ST/Zip: \_\_\_\_\_  
 Contact Person: \_\_\_\_\_ Phone #: \_\_\_\_\_ Fax #: \_\_\_\_\_  
 Email Where Follow Up Documentation Should Be Sent: \_\_\_\_\_

**REQUIRED CLINICAL DOCUMENTATION**

**Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.**

**Clinical Information, select all that apply:**

- The patient has moderate-to-severe chronic plaque psoriasis affecting at least 3% of the body surface area (BSA).
- Plaque psoriasis involves sensitive areas or areas that significantly impact daily function (e.g., palms, soles of feet, head/neck, or genitalia)
- Patient has had an inadequate response to or is intolerant to phototherapy, topical therapies, or other systemic therapies.

**LAB AND TEST RESULTS (required)**

- TB screening (submit results from within 12 months to start therapy and annually to continue therapy)
  - Annual TB screening to be done by:  Infusion Center  Referring Physician

**PRIOR FAILED THERAPIES**

Medication Failed: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_  
 Medication Failed: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_  
 Medication Failed: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_  
 Medication Failed: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_  
 Medication Failed: \_\_\_\_\_ Dates of Treatment: \_\_\_\_\_ Reason for D/C: \_\_\_\_\_